AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03154476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
Study NCT03154476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching study drug
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT00125372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib (Tarceva) and bexarotene (Targretin)
Description: Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
Study NCT02656901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: auto total endovenous anesthesia
Description: a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
Study NCT02656901 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual Desflurane anesthesia
Description: General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
Study NCT02656901 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual Sevoflurane anesthesia
Description: General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
Study NCT02656901 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual total endovenous anesthesia
Description: In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
Study NCT03610906 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor and Blood Specimens
Description: If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
Study NCT01769703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran 110/150 mg BID
Description: Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
Study NCT02020460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subdural trial lead
Study NCT02020460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural trial lead
Study NCT03604068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RecoveryRx
Description: A pulsed shortwave therapy medical device
Study NCT03604068 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RecoveryRx
Description: A sham pulsed shortwave therapy medical device
Study NCT01796262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid
Description: Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
Study NCT01796262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat germ oil
Description: Wheat germ oil 250 mg pearl b.i.d. for six months
Study NCT00917085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact
Description: Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
Study NCT01602549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (25 mg tablet)
Description: 25 mg tablet
Study NCT01602549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I: HSK21542 0.5 μg/kg
Description: intravenous injection
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I: HSK21542 1 μg/kg
Description: intravenous injection
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 0.5 μg/kg
Description: intravenous injection
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 1 μg/kg
Description: intravenous injection
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 2 μg/kg
Description: intravenous injection
Study NCT04470128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous injection
Study NCT00851253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Given in 2 fractionated doses or 5 fractionated doses
Study NCT02884830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: positive airway pressure given by a medical device through a nasal mask
Study NCT02884830 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: continuous positive airway pressure
Description: positive airway pressure given by a medical device through a nasal mask
Study NCT00960713 — intervention group
Intervention type: DRUG
Intervention: Rituximab (MABTHERA® or RITUXAN®).
Description: patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
Study NCT05066035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge.
Study NCT05066035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to >0.9 in the recovery room before discharge to the ward.
Study NCT01788072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: 24 IU taken twice daily (BID), in the morning and at noon/early afternoon
Study NCT01788072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 IU taken twice daily (BID), in the morning and at noon/early afternoon
Study NCT00453180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
Study NCT00453180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo arm will receive placebo pill for duration of study.
Study NCT03424577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6527
Description: Oral capsule
Study NCT04871581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTI-tss
Description: FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
Study NCT04871581 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to Device, but having no influence on clenching intensity
Study NCT04248400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: A 24 weeks Tai Chi training with three 1-hour section per week
Study NCT04248400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: A 24 weeks conventional exercise training with three 1-hour section per week
Study NCT00812240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT00812240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: imatinib 400 mg or 600 mg per day, per os
Study NCT02883777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein and Low Glycemic Index Diet
Description: It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
Study NCT02883777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: Conventional diet over 1 year after transplantation.
Study NCT03713957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6021
Description: GRF6021 for IV infusion
Study NCT03713957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study NCT01926470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anteroposterior approach group
Description: anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
Study NCT01926470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique approach group
Description: oblique approach group (n=104): same as anteroposterior approach group except using oblique view
Study NCT03629691 — intervention group
Intervention type: OTHER
Intervention: lung cavitation
Description: apatinib treated patients developed lung cavitation
Study NCT04409301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Special Aflac Duck (MSAD)
Description: The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
Study NCT04409301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care control
Description: Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
Study NCT02906956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred music playlist
Description: Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
Study NCT03039920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic cigarette
Description: Smoking of electronic cigarette
Study NCT03039920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette
Description: Smoking tobacco cigarette
Study NCT01263093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT01263093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT02174861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study NCT00714298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of Initial heart fatty acid binding protein and ischemia modified albumin
Description: Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
Study NCT04093635 — intervention group
Intervention type: DEVICE
Intervention: Negative Pressure Wound Therapy
Description: VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
Study NCT00121316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus Cream 1 %
Study NCT00121316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle cream (placebo cream)
Study NCT03340142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVO™
Description: Diagnose the area of a PVC or VT onset
Study NCT03424512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy
Description: Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
Study NCT00289757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 doses at 6 months interval
Study NCT03519659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose
Study NCT03519659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 5 mCi radiation dose
Description: 5 mCi 18F-FDG dose
Study NCT02685826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: single use vials administered via intravenous infusion
Study NCT02685826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: capsules for oral administration
Study NCT02685826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: tablets for oral administration
Study NCT04122846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Very much based on Unlearn your pain by Howard Schubiner.
Study NCT02743767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Introducing five different treating adaptations
Description: Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
Study NCT01977742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
Study NCT01977742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program together with a specific sudden rest-exercise training protocol
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
Study NCT04326556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective cohort for etiological and prognostic purposes
Description: Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
Study NCT02066519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise programme using a rowing machine
Description: 3 sessions per week of individualized physical training using a rowing machine during 3 months.
Study NCT00605722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: 5 mg/kg iv on day 1 of each 2 week cycle.
Study NCT04222530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Linear EUS first
Description: Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
Study NCT01466335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet
Study NCT01466335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study NCT03519659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 2.5 mCi radiation dose
Description: 2.5 mCi 18F-FDG dose
Study NCT03519659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with 6.5 mCi radiation dose
Description: 6.5 mCi 18F-FDG dose
Study NCT03519659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with not yet determined radiation dose
Description: We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
Study NCT00459225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron (ferrous sulfate)
Description: The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
Study NCT03400072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised APA program
Description: Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
Study NCT04222530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ME-NBI first
Description: Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
Study NCT02314676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Study NCT02159625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Compression Elastic Support
Description: The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
Study NCT00888225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Eccentric exercise treatment performed at home with three sets of 15 repetitions daily